31m
Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287
Results to be discussed in KOL event today at 10 a.m. ETBETHESDA, Md., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback